Base de datos : MEDLINE
Búsqueda : fiebre [Palabras]
Referencias encontradas : 199475 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 19948 va a la página                         

  1 / 199475 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29505533
[Au] Autor:Asakura K; Yanai S; Nakamura S; Kawaski K; Eizuka M; Ishida K; Endo M; Sugai T; Migita K; Matsumoto T
[Ad] Dirección:Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University.
[Ti] Título:Familial Mediterranean fever mimicking Crohn disease: A case report.
[So] Fuente:Medicine (Baltimore);97(1):e9547, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:RATIONALE: Familial Mediterranean fever (FMF) is the most common form of autoinflammatory disease. We report a rare case of FMF with gastrointestinal lesions mimicking Crohn disease. PATIENT CONCERNS: A 21-year-old Japanese man was referred to our institution, complaining of refractory diarrhea and weight loss of 14 kg during the past two years. He had presented with recurrent fever, abdominal pain, anal fistula and stomatitis. His father and one of his brothers had ulcerative colitis. Colonoscopy revealed longitudinal ulcers in the terminal ileum and aphthous erosions in the colorectum. Esophagogastroduodenoscopy revealed multiple linear erosions in the gastric corpus and circular erosions in the duodenal second portion. Biopsy from these lesions failed to detect epithelioid cell granulomas. DIAGNOSES: Analysis of the genomic DNA revealed compound heterozygous mutations of E148Q/L110P in exon 2 of MEFV gene, suggesting a diagnosis of FMF. INTERVENTIONS: The patient was subsequently given 0.5 mg of colchicine per day. OUTCOMES: Follow-up colonoscopy 6 months later demonstrated that both the longitudinal ulcers in the terminal ileum and aphthous lesions in the colorectum had completely disappeared. LESSONS: Our case suggests that patients with FMF possibly manifest gastrointestinal lesions mimicking Crohn disease.
[Mh] Términos MeSH primario: Enfermedad de Crohn/diagnóstico
Fiebre Mediterránea Familiar/diagnóstico
[Mh] Términos MeSH secundario: Colonoscopía
Diagnóstico Diferencial
Seres Humanos
Masculino
Adulto Joven
[Pt] Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180309
[Lr] Fecha última revisión:180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009547


  2 / 199475 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29377908
[Au] Autor:Awine T; Malm K; Peprah NY; Silal SP
[Ad] Dirección:Modelling and Simulation Hub, Africa, Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.
[Ti] Título:Spatio-temporal heterogeneity of malaria morbidity in Ghana: Analysis of routine health facility data.
[So] Fuente:PLoS One;13(1):e0191707, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Malaria incidence is largely influenced by vector abundance. Among the many interconnected factors relating to malaria transmission, weather conditions such as rainfall and temperature are known to create suitable environmental conditions that sustain reproduction and propagation of anopheles mosquitoes and malaria parasites. In Ghana, climatic conditions vary across the country. Understanding the heterogeneity of malaria morbidity using data sourced from a recently setup data repository for routine health facility data could support planning. METHODS: Monthly aggregated confirmed uncomplicated malaria cases from the District Health Information Management System and average monthly rainfall and temperature records obtained from the Ghana Meteorological Agency from 2008 to 2016 were analysed. Univariate time series models were fitted to the malaria, rainfall and temperature data series. After pre-whitening the morbidity data, cross correlation analyses were performed. Subsequently, transfer function models were developed for the relationship between malaria morbidity and rainfall and temperature. RESULTS: Malaria morbidity patterns vary across zones. In the Guinea savannah, morbidity peaks once in the year and twice in both the Transitional forest and Coastal savannah, following similar patterns of rainfall at the zonal level. While the effects of rainfall on malaria morbidity are delayed by a month in the Guinea savannah and Transitional Forest zones those of temperature are delayed by two months in the Transitional forest zone. In the Coastal savannah however, incidence of malaria is significantly associated with two months lead in rainfall and temperature. CONCLUSION: Data captured on the District Health Information Management System has been used to demonstrate heterogeneity in the dynamics of malaria morbidity across the country. Timing of these variations could guide the deployment of interventions such as indoor residual spraying, Seasonal Malaria Chemoprevention or vaccines to optimise effectiveness on zonal basis.
[Mh] Términos MeSH primario: Instituciones de Salud
Malaria/epidemiología
[Mh] Términos MeSH secundario: Clima
Ghana/epidemiología
Seres Humanos
Malaria/transmisión
Estaciones del Año
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180309
[Lr] Fecha última revisión:180309
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:180130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191707


  3 / 199475 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29278025
[Au] Autor:Kataoka H; Nakano J; Kondo Y; Honda Y; Sakamoto J; Origuchi T; Okita M
[Ad] Dirección:1 Department of Locomotive Rehabilitation Science, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki, Japan.
[Ti] Título:The influence of aging on the effectiveness of heat stress in preventing disuse muscle atrophy.
[So] Fuente:Physiol Int;104(4):316-328, 2017 Dec 01.
[Is] ISSN:2498-602X
[Cp] País de publicación:Hungary
[La] Idioma:eng
[Ab] Resumen:This study examined the aging effect on disuse muscle atrophy prevention using heat stress. Wistar rats aged 7 and 60 weeks were divided into three groups as follows: control, immobilized (Im), and immobilized and heat stressed (ImH). Heat stress was given by immersing the hindlimbs in hot water (42 °C) for 60 min, once in every 3 days and the gastrocnemius (GAS) and soleus (SOL) muscles were extracted after 14 days. Muscle-fiber types were classified using ATPase staining. Heat shock protein 70 (HSP70) was assessed through Western blotting. In GAS muscle of both groups and SOL muscle of 7-week-old rats, the fiber diameter of each muscle type in the ImH group significantly increased compared with that in the Im group. However, this could not be observed in the SOL muscle of the 60-week-old rats. The increased percentage of type-I fibers and variability of types I and II muscle-fiber diameter were evident in the SOL muscle of the 60-week rats. HSP70 was significantly elevated in the ImH group compared with in the Im group in both muscle types of both age groups. Thus, effectiveness of heat stress in the prevention of disuse muscle atrophy appears unsatisfactory in aging muscle fibers.
[Mh] Términos MeSH primario: Envejecimiento
Proteínas HSP70 de Choque Térmico/metabolismo
Hipertermia Inducida/métodos
Músculo Esquelético/fisiopatología
Trastornos Musculares Atróficos/prevención & control
Trastornos Musculares Atróficos/fisiopatología
[Mh] Términos MeSH secundario: Animales
Respuesta al Choque Térmico
Masculino
Fibras Musculares Esqueléticas/patología
Músculo Esquelético/patología
Trastornos Musculares Atróficos/diagnóstico
Ratas
Ratas Wistar
Resultado del Tratamiento
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (HSP70 Heat-Shock Proteins)
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180309
[Lr] Fecha última revisión:180309
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:171227
[St] Status:MEDLINE
[do] DOI:10.1556/2060.104.2017.4.1


  4 / 199475 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29200851
[Au] Autor:Mondal S; Manivasagan P; Bharathiraja S; Santha Moorthy M; Kim HH; Seo H; Lee KD; Oh J
[Ad] Dirección:Marine-Integrated Bionics Research Center.
[Ti] Título:Magnetic hydroxyapatite: a promising multifunctional platform for nanomedicine application.
[So] Fuente:Int J Nanomedicine;12:8389-8410, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicación:New Zealand
[La] Idioma:eng
[Ab] Resumen:In this review, specific attention is paid to the development of nanostructured magnetic hydroxyapatite (MHAp) and its potential application in controlled drug/gene delivery, tissue engineering, magnetic hyperthermia treatment, and the development of contrast agents for magnetic resonance imaging. Both magnetite and hydroxyapatite materials have excellent prospects in nanomedicine with multifunctional therapeutic approaches. To date, many research articles have focused on biomedical applications of nanomaterials because of which it is very difficult to focus on any particular type of nanomaterial. This study is possibly the first effort to emphasize on the comprehensive assessment of MHAp nanostructures for biomedical applications supported with very recent experimental studies. From basic concepts to the real-life applications, the relevant characteristics of magnetic biomaterials are patented which are briefly discussed. The potential therapeutic and diagnostic ability of MHAp-nanostructured materials make them an ideal platform for future nanomedicine. We hope that this advanced review will provide a better understanding of MHAp and its important features to utilize it as a promising material for multifunctional biomedical applications.
[Mh] Términos MeSH primario: Durapatita/química
Magnetismo
Nanomedicina/métodos
[Mh] Términos MeSH secundario: Animales
Sistemas de Liberación de Medicamentos
Seres Humanos
Hipertermia Inducida
Nanopartículas de Magnetita/química
Andamios del Tejido/química
[Pt] Tipo de publicación:JOURNAL ARTICLE; REVIEW
[Nm] Nombre de substancia:
0 (Magnetite Nanoparticles); 91D9GV0Z28 (Durapatite)
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180309
[Lr] Fecha última revisión:180309
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:171205
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S147355


  5 / 199475 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29030319
[Au] Autor:Dutta S; Celestine MJ; Khanal S; Huddleston A; Simms C; Arca JF; Mitra A; Heller L; Kraj PJ; Ledizet M; Anderson JF; Neelakanta G; Holder AA; Sultana H
[Ad] Dirección:Department of Biological Sciences, Old Dominion University, Norfolk, VA, USA.
[Ti] Título:Coordination of different ligands to copper(II) and cobalt(III) metal centers enhances Zika virus and dengue virus loads in both arthropod cells and human keratinocytes.
[So] Fuente:Biochim Biophys Acta;1862(1):40-50, 2018 01.
[Is] ISSN:0006-3002
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:Trace elements such as copper and cobalt have been associated with virus-host interactions. However, studies to show the effect of conjugation of copper(II) or cobalt(III) metal centers to thiosemicarbazone ligand(s) derived from either food additives or mosquito repellent such as 2-acetylethiazole or citral, respectively, on Zika virus (ZIKV) or dengue virus (serotype 2; DENV2) infections have not been explored. In this study, we show that four compounds comprising of thiosemicarbazone ligand derived from 2-acetylethiazole viz., (E)-N-ethyl-2-[1-(thiazol-2-yl)ethylidene]hydrazinecarbothioamide (acetylethTSC) (compound 1), a copper(II) complex with acetylethTSC as a ligand (compound 2), a thiosemicarbazone ligand-derived from citral (compound 3) and a cobalt(III) complex with a citral-thiosemicarbazone ligand (compound 4) increased DENV2 and ZIKV replication in both mosquito C6/36 cells and human keratinocytes (HaCaT cells). Treatment of both cell lines with compounds 2 or 4 showed increased dengue viral titers at all three tested doses. Enhanced dengue viral plaque formation was also noted at the tested dose of 100µM, suggesting higher production of infectious viral particles. Treatment with the compounds 2 or 4 enhanced ZIKV and DENV2 RNA levels in HeLa cell line and primary cultures of mouse bone marrow derived dendritic cells. Also, pre- or post treatments with conjugated compounds 2 or 4 showed higher loads of ZIKV or DENV2 envelope (E) protein in HaCaT cells. No changes in loads of E-protein were found in ZIKV-infected C6/36 cells, when compounds were treated after infection. In addition, we tested bis(1,10-phenanthroline)copper(II) chloride ([Cu(phen) ]Cl , (compound 5) and tris(1,10-phenanthroline)cobalt(III) chloride ([Co(phen) ]Cl , (compound 6) that also showed enhanced DENV2 loads. Also, we found that copper(II) chloride dehydrate (CuCl ·2H O) or cobalt(II) chloride hexahydrate (CoCl ·6H O) alone had no effects as "free" cations. Taken together, these findings suggest that use of Cu(II) or Co(III) conjugation to organic compounds, in insect repellents and/or food additives could enhance DENV2/ZIKV loads in human cells and perhaps induce pathogenesis in infected individuals or individuals pre-exposed to such conjugated complexes. IMPORTANCE: Mosquito-borne diseases are of great concern to the mankind. Use of chemicals/repellents against mosquito bites and transmission of microbes has been the topic of interest for many years. Here, we show that thiosemicarbazone ligand(s) derived from 2-acetylethiazole or citral or 1,10-phenanthroline upon conjugation with copper(II) or cobalt(III) metal centers enhances dengue virus (serotype 2; DENV2) and/or Zika virus (ZIKV) infections in mosquito, mouse and human cells. Enhanced ZIKV/DENV2 capsid mRNA or envelope protein loads were evident in mosquito cells and human keratinocytes, when treated with compounds before/after infections. Also, treatment with copper(II) or cobalt(III) conjugated compounds increased viral titers and number of plaque formations. These studies suggest that conjugation of compounds in repellents/essential oils/natural products/food additives with copper(II) or cobalt(III) metal centers may not be safe, especially in tropical and subtropical places, where several dengue infection cases and deaths are reported annually or in places with increased ZIKV caused microcephaly.
[Mh] Términos MeSH primario: Cobalto
Complejos de Coordinación
Cobre
Virus del Dengue/metabolismo
Queratinocitos/virología
Carga Viral/efectos de los fármacos
Virus Zika/metabolismo
[Mh] Términos MeSH secundario: Animales
Cercopithecus aethiops
Cobalto/química
Cobalto/farmacología
Complejos de Coordinación/química
Complejos de Coordinación/farmacología
Cobre/química
Cobre/farmacología
Culicidae
Células HeLa
Seres Humanos
Queratinocitos/metabolismo
Queratinocitos/patología
Células Vero
Proteínas del Envoltorio Viral
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nombre de substancia:
0 (Coordination Complexes); 0 (Viral Envelope Proteins); 3G0H8C9362 (Cobalt); 789U1901C5 (Copper)
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180309
[Lr] Fecha última revisión:180309
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:171015
[St] Status:MEDLINE


  6 / 199475 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28456663
[Au] Autor:Singh S; Anupriya MG; Sreekumar E
[Ad] Dirección:Molecular Virology Laboratory, Rajiv Gandhi Centre for Biotechnology (RGCB), Thycaud P.O., Thiruvananthapuram 695014, Kerala, India.
[Ti] Título:Comparative whole genome analysis of dengue virus serotype-2 strains differing in trans-endothelial cell leakage induction in vitro.
[So] Fuente:Infect Genet Evol;52:34-43, 2017 Aug.
[Is] ISSN:1567-7257
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:The role of genetic differences among dengue virus (DENV) in causing increased microvascular permeability is less explored. In the present study, we compared two closely related DENV serotype-2 strains of Cosmopolitan genotype for their in vitro infectivity phenotype and ability to induce trans-endothelial leakage. We found that these laboratory strains differed significantly in infecting human microvascular endothelial cells (HMEC-1) and hepatocytes (Huh7), two major target cells of DENV in in vivo infections. There was a reciprocal correlation in infectivity and vascular leakage induced by these strains, with the less infective strain inducing more trans-endothelial cell leakage in HMEC-1 monolayer upon infection. The cells infected with the strain capable of inducing more permeability were found to secrete more Non-Structural protein (sNS1) into the culture supernatant. A whole genome analysis revealed 37 predicted amino acid changes and changes in the secondary structure of 3' non-translated region between the strains. But none of these changes involved the signal sequence coded by the C-terminal of the Envelope protein and the two glycosylation sites within the NS1 protein critical for its secretion, and the N-terminal NS2A sequence important for surface targeting of NS1. The strain that secreted lower levels of NS1 and caused less leakage had two mutations within the NS1 protein coding region, F103S and T146I that significantly changed amino acid properties. A comparison of the sequences of the two strains with published sequences of various DENV strains known to cause clinically severe dengue identified a number of amino acid changes which could be implicated as possible key genetic differences. Our data supports the earlier observations that the vascular leakage induction potential of DENV strains is linked to the sNS1 levels. The results also indicate that viral genetic determinants, especially the mutations within the NS1 coding region, could affect this critical phenotype of DENV strains.
[Mh] Términos MeSH primario: Virus del Dengue/fisiología
Células Endoteliales/virología
Hepatocitos/virología
Proteínas no Estructurales Virales/genética
[Mh] Términos MeSH secundario: Regiones no Traducidas 3'
Animales
Permeabilidad Capilar
Línea Celular
Virus del Dengue/genética
Células Endoteliales/citología
Variación Genética
Genoma Viral
Hepatocitos/citología
Seres Humanos
Estructura Secundaria de Proteína
Análisis de Secuencia de ARN
Proteínas no Estructurales Virales/química
Proteínas no Estructurales Virales/secreción
Replicación Viral/fisiología
[Pt] Tipo de publicación:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (3' Untranslated Regions); 0 (NS1 protein, Dengue virus type 2); 0 (Viral Nonstructural Proteins)
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180309
[Lr] Fecha última revisión:180309
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170501
[St] Status:MEDLINE


  7 / 199475 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28457675
[Au] Autor:Wichgers Schreur PJ; van Keulen L; Kant J; Kortekaas J
[Ad] Dirección:Department of Virology, Wageningen Bioveterinary Research, Lelystad, The Netherlands. Electronic address: paul.wichgersschreur@wur.nl.
[Ti] Título:Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy.
[So] Fuente:Vaccine;35(23):3123-3128, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:Rift Valley fever virus (RVFV) causes severe and recurrent outbreaks on the African continent and the Arabian Peninsula and continues to expand its habitat. This mosquito-borne virus, belonging to the genus Phlebovirus of the family Bunyaviridae contains a tri-segmented negative-strand RNA genome. Previously, we developed four-segmented RVFV (RVFV-4s) variants by splitting the M-genome segment into two M-type segments each encoding one of the structural glycoproteins; Gn or Gc. Vaccination/challenge experiments with mice and lambs subsequently showed that RVFV-4s induces protective immunity against wild-type virus infection after a single administration. To demonstrate the unprecedented safety of RVFV-4s, we here report that the virus does not cause encephalitis after intranasal inoculation of mice. A study with pregnant ewes subsequently revealed that RVFV-4s does not cause viremia and does not cross the ovine placental barrier, as evidenced by the absence of teratogenic effects and virus in the blood and organs of the fetuses. Altogether, these results show that the RVFV-4s vaccine virus can be applied safely in pregnant ewes.
[Mh] Términos MeSH primario: Fiebre del Valle del Rift/prevención & control
Virus de la Fiebre del Valle del Rift/genética
Virus de la Fiebre del Valle del Rift/inmunología
Enfermedades de las Ovejas/prevención & control
Vacunas Virales/administración & dosificación
Vacunas Virales/efectos adversos
[Mh] Términos MeSH secundario: Animales
Anticuerpos Neutralizantes/sangre
Anticuerpos Antivirales/sangre
Encefalitis Viral/etiología
Encefalitis Viral/veterinaria
Femenino
Genoma Viral/genética
Genoma Viral/inmunología
Ratones
Embarazo
Fiebre del Valle del Rift/virología
Virus de la Fiebre del Valle del Rift/química
Ovinos
Oveja Doméstica/inmunología
Teratógenos
Vacunas Atenuadas/administración & dosificación
Vacunas Atenuadas/efectos adversos
Vacunas Atenuadas/inmunología
Vacunas Virales/inmunología
Viremia/prevención & control
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Teratogens); 0 (Vaccines, Attenuated); 0 (Viral Vaccines)
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180308
[Lr] Fecha última revisión:180308
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170502
[St] Status:MEDLINE


  8 / 199475 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28457672
[Au] Autor:Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
[Ad] Dirección:Instituto Nacional de Salud Pública, Mexico. Electronic address: jdiaz@insp.mx.
[Ti] Título:Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
[So] Fuente:Vaccine;35(23):3116-3122, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:IMPORTANCE: In a previous study on booster vaccination, we reported that two aerosolized MMR vaccines were as safe and immunogenic as injectable vaccines containing the same antigens. We now present results of antibody persistence one year after immunization. OBJECTIVE: To assess the antibody persistence for measles, mumps, and rubella one year following booster immunization. METHODS: We performed clinical and serological follow-up of participants in a previous study of Mexican children aged 6-7years, in which participants were randomized to four groups receiving, by aerosolized or by injection, the MMR SII vaccine (Serum Institute of India), or the MMR II (Merck Sharp & Dhome). We evaluated the antibody persistence by PRN test for measles and by ELISA for rubella and mumps. The occurrence of clinical events was evaluated via periodic visits of a nurse team to children's schools and homes. RESULTS: Of the 260 initial participants, 241 completed one-year follow-up. There were only statistically significant differences in baseline seropositivity for mumps. One year after immunization, seropositivity in all groups was 100% for measles and rubella. The seropositivity rank for mumps was from 90.3% for the injected vaccine MMR II to 96.6% for vaccine MMR SII applied by aerosol; these differences were not statistically significant. With exception of the aerosolized vaccine MMR SII for the geometric mean titer (GMT) for measles, all study groups presented declination of GMT for the three viruses. The difference between the aerosolized vaccines MMR SII and MMR RII was statistically significant for mumps antibodies. Only mild clinical events were identified. CONCLUSION: Under conditions of no endemic transmission for measles and rubella, and of low circulation of mumps virus, school-aged children remained seropositive to the three viruses one year following booster immunization. The study was registered under CMN 2010-005 number at COFEPRIS (National Regulatory Authority).
[Mh] Términos MeSH primario: Anticuerpos Antivirales/sangre
Inmunización Secundaria/métodos
Virus del Sarampión/inmunología
Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología
Virus de la Parotiditis/inmunología
[Mh] Términos MeSH secundario: Aerosoles
Niño
Ensayo de Inmunoadsorción Enzimática
Femenino
Estudios de Seguimiento
Seres Humanos
Inmunización Secundaria/efectos adversos
India/epidemiología
Inyecciones
Masculino
Sarampión/epidemiología
Sarampión/inmunología
Sarampión/prevención & control
Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación
Vacuna contra el Sarampión-Parotiditis-Rubéola/efectos adversos
Paperas/epidemiología
Paperas/inmunología
Paperas/prevención & control
Rubéola (Sarampión Alemán)/epidemiología
Rubéola (Sarampión Alemán)/inmunología
Rubéola (Sarampión Alemán)/prevención & control
Virus de la Rubéola/inmunología
Estudios Seroepidemiológicos
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Aerosols); 0 (Antibodies, Viral); 0 (Measles-Mumps-Rubella Vaccine); 0 (rubella antibodies)
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180308
[Lr] Fecha última revisión:180308
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170502
[St] Status:MEDLINE


  9 / 199475 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28456529
[Au] Autor:Shankar MB; Staples JE; Meltzer MI; Fischer M
[Ad] Dirección:Division for Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C-18, Atlanta, GA 30329, USA. Electronic address: kiu8@cdc.gov.
[Ti] Título:Cost effectiveness of a targeted age-based West Nile virus vaccination program.
[So] Fuente:Vaccine;35(23):3143-3151, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: West Nile virus (WNV) is the leading cause of domestically-acquired arboviral disease in the United States. Several WNV vaccines are in various stages of development. We estimate the cost-effectiveness of WNV vaccination programs targeting groups at increased risk for severe WNV disease. METHODS: We used a mathematical model to estimate costs and health outcomes of vaccination with WNV vaccine compared to no vaccination among seven cohorts, spaced at 10year intervals from ages 10 to 70years, each followed until 90-years-old. U.S. surveillance data were used to estimate WNV neuroinvasive disease incidence. Data for WNV seroprevalence, acute and long-term care costs of WNV disease patients, quality-adjusted life-years (QALYs), and vaccine characteristics were obtained from published reports. We assumed vaccine efficacy to either last lifelong or for 10years with booster doses given every 10years. RESULTS: There was a statistically significant difference in cost-effectiveness ratios across cohorts in both models and all outcomes assessed (Kruskal-Wallis test p<0.0001). The 60-year-cohort had a mean cost per neuroinvasive disease case prevented of $664,000 and disability averted of $1,421,000 in lifelong model and $882,000 and $1,887,000, respectively in 10-year immunity model; these costs were statistically significantly lower than costs for other cohorts (p<0.0001). Vaccinating 70-year-olds had the lowest cost per death averted in both models at around $4.7 million (95%CI $2-$8 million). Cost per disease case averted was lowest among 40- and 50-year-old cohorts and cost per QALY saved lowest among 60-year cohorts in lifelong immunity model. The models were most sensitive to disease incidence, vaccine cost, and proportion of persons developing disease among infected. CONCLUSIONS: Age-based WNV vaccination program targeting those at higher risk for severe disease is more cost-effective than universal vaccination. Annual variation in WNV disease incidence, QALY weights, and vaccine costs impact the cost effectiveness ratios.
[Mh] Términos MeSH primario: Programas de Inmunización/economía
Vacunas contra el Virus del Nilo Occidental/economía
[Mh] Términos MeSH secundario: Adolescente
Adulto
Factores de Edad
Anciano
Anciano de 80 o más Años
Niño
Análisis Costo-Beneficio
Femenino
Seres Humanos
Inmunización Secundaria/economía
Masculino
Cadenas de Markov
Mediana Edad
Método de Montecarlo
Años de Vida Ajustados por Calidad de Vida
Factores de Riesgo
Estudios Seroepidemiológicos
Estados Unidos/epidemiología
Vacunación/economía
Fiebre del Nilo Occidental/epidemiología
Fiebre del Nilo Occidental/prevención & control
Vacunas contra el Virus del Nilo Occidental/administración & dosificación
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (West Nile Virus Vaccines)
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180308
[Lr] Fecha última revisión:180308
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170501
[St] Status:MEDLINE


  10 / 199475 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28456527
[Au] Autor:Perry J; Towers CV; Weitz B; Wolfe L
[Ad] Dirección:Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, University of Tennessee Medical Center, Knoxville, TN, United States.
[Ti] Título:Patient reaction to Tdap vaccination in pregnancy.
[So] Fuente:Vaccine;35(23):3064-3066, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: The current obstetrical recommendation is to routinely administer the tetanus, diphtheria, and acellular pertussis (Tdap) vaccination during every pregnancy regardless of a patient's prior history. There are minimal data that have prospectively evaluated solicited patient response to this treatment plan. The study objective was to evaluate patient reaction following receipt of Tdap vaccination during pregnancy. METHODS: This was a prospective observational study conducted from May 2014 through March 2016. The study design involved solicited patient reaction within 1-7days after the administration of the Tdap vaccine. Data collected included pain or soreness, swelling, and/or redness at the injection site, as well as, fever and generalized body aches. Statistical analysis involved simple percentages with Poisson binomial 95% confidence intervals with Chi-square and Fisher's exact comparisons where appropriate. RESULTS: A total of 737 patients were evaluated and 496 (67%, 95% Confidence Interval [CI] 64-71%) were found to have at least 1 reaction to the vaccination and 187 (25%, 95% CI 22-29%) had 2 reactions or more. Overall, the majority of patients stated that the vaccination was tolerated. However, 24 (3%, 95% CI 2-5%) of the study population stated that they would not accept receipt of Tdap in a subsequent pregnancy because of the response that occurred in the current pregnancy. CONCLUSION: These data demonstrate that maternal reactions following receipt of Tdap are common (two-thirds of the study population). A potential concern is the finding that some patients might refuse a repeat vaccination in a subsequent pregnancy due to these reactions. If further research reveals similar findings, a pertussis only vaccine for pregnant patients might need to be evaluated.
[Mh] Términos MeSH primario: Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/administración & dosificación
Vacunas contra Difteria, Tétanos y Tos Ferina Acelular/efectos adversos
Complicaciones Infecciosas del Embarazo/prevención & control
[Mh] Términos MeSH secundario: Adulto
Difteria/prevención & control
Femenino
Fiebre/etiología
Seres Humanos
Madres/psicología
Mialgia/etiología
Dolor/etiología
Embarazo
Estudios Prospectivos
Tétanos/prevención & control
Vacunación
Tos Ferina/prevención & control
[Pt] Tipo de publicación:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nombre de substancia:
0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180308
[Lr] Fecha última revisión:180308
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170501
[St] Status:MEDLINE



página 1 de 19948 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud